scispace - formally typeset
G

Guillermo Sánchez

Researcher at National University of Colombia

Publications -  33
Citations -  1744

Guillermo Sánchez is an academic researcher from National University of Colombia. The author has contributed to research in topics: Rheumatoid arthritis & Medicine. The author has an hindex of 9, co-authored 28 publications receiving 1612 citations.

Papers
More filters
Journal ArticleDOI

Physician advice for smoking cessation

TL;DR: This study found no statistically significant differences in death rates at 20 years follow-up, though there is a small additional benefit of more intensive interventions compared to very brief interventions.
Journal ArticleDOI

Sun protection for preventing basal cell and squamous cell skin cancers.

TL;DR: This study compared the daily application of sunscreen compared with discretionary use of sunscreen, with or without beta-carotene administration, in the general population and found this study to be at low risk of bias for domains such as allocation, blinding, and incomplete outcome data.
Journal ArticleDOI

Incidencia de cáncer de piel en Colombia, años 2003-2007

TL;DR: In Colombia, the incidencia de cancer de piel in the periodo 2003-2007 was 1.2:1, a razon varones:mujeres, femenines, and franjas de edad as mentioned in this paper.
Journal ArticleDOI

Rheumatoid factor as predictor of response to treatment with anti-TNF alpha drugs in patients with rheumatoid arthritis: Results of a cohort study.

TL;DR: It is suggested that remission is less frequent and severe disability more frequent in RF-positive patients treated with anti-TNF alpha agents than inRF-negative patients, and the incidence rate ratio (IRR) for each outcome is calculated by adjusting for possible confounders using the Poisson regression method.
Journal ArticleDOI

Treatment of rheumatoid arthritis with methotrexate alone and in combination with other conventional DMARDs using the T2T strategy. A cohort study.

TL;DR: This study, developed in a cohort of patients with RA with moderate or severe disease activity who were treated with MTX by itself or combined with other non-biological DMARDs under T2T strategy, showed a decrease in the severity of disease activity in 80 % of patients.